Quinacrine Trial for Cutaneous Lupus Erythematosus Underway
A clinical trial is currently evaluating the safety and efficacy of quinacrine in treating cutaneous lupus erythematosus (CLE), with a total participation duration of 28 weeks.
Therapeutic Area
Therapeutic area intelligence for Cutaneous Lupus Erythematosus with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.